{"protocolSection": {"identificationModule": {"nctId": "NCT04203797", "orgStudyIdInfo": {"id": "R668-AS-1903"}, "secondaryIdInfos": [{"id": "2019-002742-20", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Regeneron Pharmaceuticals", "class": "INDUSTRY"}, "briefTitle": "A Study to Evaluate the Effect of Dupilumab on Exercise Capacity in Adult Patients With Asthma", "officialTitle": "A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Dupilumab on Exercise Capacity in Patients With Moderate-to-Severe Asthma"}, "statusModule": {"statusVerifiedDate": "2024-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2020-07-16", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2023-07-15", "type": "ACTUAL"}, "completionDateStruct": {"date": "2023-07-15", "type": "ACTUAL"}, "studyFirstSubmitDate": "2019-12-17", "studyFirstSubmitQcDate": "2019-12-17", "studyFirstPostDateStruct": {"date": "2019-12-18", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2024-03-21", "resultsFirstSubmitQcDate": "2024-03-21", "resultsFirstPostDateStruct": {"date": "2024-04-18", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2024-03-21", "lastUpdatePostDateStruct": {"date": "2024-04-18", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Regeneron Pharmaceuticals", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "The primary objective of the study is to demonstrate that dupilumab treatment improves exercise capacity in patients with moderate-to-severe asthma.\n\nThe secondary objectives of the study are:\n\n* To demonstrate that dupilumab treatment increases physical activity of daily living in patients with moderate-to-severe asthma\n* To demonstrate that dupilumab treatment improves pre- and post-exercise lung function in patients with moderate-to-severe asthma"}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 40, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "dupilumab", "type": "EXPERIMENTAL", "description": "A loading dose at the start of the treatment followed by once every two weeks (Q2W).", "interventionNames": ["Drug: dupilumab"]}, {"label": "Matching placebo", "type": "EXPERIMENTAL", "description": "Matching dupilumab", "interventionNames": ["Drug: Matching placebo"]}], "interventions": [{"type": "DRUG", "name": "dupilumab", "description": "Pre-filled syringe administered by subcutaneous (SC) injections", "armGroupLabels": ["dupilumab"], "otherNames": ["Dupixent\u00ae", "SAR231893"]}, {"type": "DRUG", "name": "Matching placebo", "description": "Pre-filled syringe administered by subcutaneous (SC)", "armGroupLabels": ["Matching placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline to Week 12 in Constant Work Rate Exercise Endurance Time - CWRET (Constant Work Rate Exercise Test)", "description": "CWRET (Constant Work Rate Exercise Test) will be performed on an electromagnetically-braked cycle ergometer in an exercise physiology laboratory overseen by a trained pulmonologist or medical doctor designee.", "timeFrame": "Up to week 12"}], "secondaryOutcomes": [{"measure": "Change From Baseline to Week 12 in Average Number of Steps Walked Per Day", "description": "Based on accelerometry data", "timeFrame": "Up to week 12"}, {"measure": "Change From Baseline to Week 12 in Total Energy Expenditure", "description": "Metabolic equivalents of tasks \\[METs\\]. Based on accelerometry data", "timeFrame": "Up to week 12"}, {"measure": "Change From Baseline to Week 12 in the Mean Duration of Moderate-to-vigorous Physical Activity", "description": "Defined as \u22653 METs. Based on accelerometry data", "timeFrame": "Up to week 12"}, {"measure": "Change From Baseline to Week 12 in Pre- and Post-exercise Forced Expiratory Volume in One Second (FEV1)", "description": "Based on spirometry data", "timeFrame": "Up to week 12"}]}, "eligibilityModule": {"eligibilityCriteria": "Key Inclusion Criteria:\n\n* A physician diagnosis of asthma\n* Pre-bronchodilator FEV1 between 30% and 75% predicted at both the screening and baseline visits\n* Bronchodilator reversibility defined as \\>200 mL and 12% increase in FEV1 post-administration of a short-acting beta agonist (SABA). A patient may also qualify if there is a documented history of bronchodilator reversibility or positive methacholine challenge test within 12 months prior to the screening visit\n* Stable background therapy for at least 3 months with a stable dose \u22654 weeks prior to the baseline visit of a medium-to-high dose ICS (fluticasone propionate \u2265250 to 1000 \u03bcg twice daily \\[BID\\] or equivalent) in combination with at least a second controller medication (eg, long-acting beta agonist \\[LABA\\], long-acting muscarinic antagonist \\[LAMA\\], leukotriene receptor antagonist \\[LTRA\\], theophylline, etc.); a third controller is allowed and with the same stabilization requirements\n* Blood eosinophil count \u2265300 cells/\u03bcL for patients not on maintenance OCS at the screening visit\n* ACQ-5 score \u22651.5 at the screening and baseline visits\n\nKey Exclusion Criteria:\n\n* Body mass index \\>35 kg/m2 at screening\n* Current smoking, vaping or tobacco chewing or cessation of any of these within 6 months prior to randomization, or \\>10 pack years smoking history\n* Patients who require supplemental oxygen at screening\n* Clinically significant cardiac disease as described in the protocol\n* Uncontrolled hypertension at screening or baseline\n* Participation in exercise or physical rehabilitation program within last 6 months prior to screening or planned during the study\n* Previous use of dupilumab\n* Anti-IgE therapy (eg, omalizumab \\[Xolair\u00ae\\]) within 130 days prior to visit 1 or any other biologic therapy (including anti-IL5, anti-IL-5R, anti-IL4R\u03b1, anti-IL-13 mAb) or systemic immunosuppressant (eg, methotrexate, any anti-tumor necrosis factor mAbs, Janus kinase inhibitors, B- and/or T-cell targeted immunosuppressive therapies) to treat inflammatory disease or autoimmune disease (eg, rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis) and other diseases, within 3 months or 5 half-lives prior to screening, whichever is longer\n* Exposure to another investigative drug (monoclonal antibodies as well as small molecules) within a period prior to screening, of \\<3 months or \\<5 half-lives (whichever is longer)\n* Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study\n* Women of childbearing potential (WOCBP)\\* who are unwilling to practice highly effective contraception prior to the initial dose/start of the first treatment, during the study, and for at least 12 weeks after the last dose\n\nNOTE: Other protocol defined inclusion/exclusion criteria apply", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "55 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Clinical Trials Management", "affiliation": "Regeneron Pharmaceuticals", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Palos Verdes Medical Group (PVMG); Peninsula Research Associates (PRA)", "city": "Rolling Hills Estates", "state": "California", "zip": "90274", "country": "United States", "geoPoint": {"lat": 33.78779, "lon": -118.35813}}, {"facility": "UCLA Medical Center - Harbor", "city": "Torrance", "state": "California", "zip": "90509", "country": "United States", "geoPoint": {"lat": 33.83585, "lon": -118.34063}}, {"facility": "Allianz Research Institute", "city": "Westminster", "state": "California", "zip": "92683", "country": "United States", "geoPoint": {"lat": 33.75918, "lon": -118.00673}}, {"facility": "University of Iowa Hospitals & Clinics-Roy J. and Lucille A. Carver College of Medicine", "city": "Iowa City", "state": "Iowa", "zip": "52242", "country": "United States", "geoPoint": {"lat": 41.66113, "lon": -91.53017}}, {"facility": "University Of Kansas Medical Center", "city": "Kansas City", "state": "Kansas", "zip": "66160", "country": "United States", "geoPoint": {"lat": 39.11417, "lon": -94.62746}}, {"facility": "Infinity Medical Research", "city": "North Dartmouth", "state": "Massachusetts", "zip": "02747", "country": "United States", "geoPoint": {"lat": 41.63899, "lon": -70.97032}}, {"facility": "University of Michigan", "city": "Ann Arbor", "state": "Michigan", "zip": "48109", "country": "United States", "geoPoint": {"lat": 42.27756, "lon": -83.74088}}, {"facility": "American Health Research", "city": "Charlotte", "state": "North Carolina", "zip": "28277", "country": "United States", "geoPoint": {"lat": 35.22709, "lon": -80.84313}}, {"facility": "UH Cleveland Medical Center", "city": "Cleveland", "state": "Ohio", "zip": "44106", "country": "United States", "geoPoint": {"lat": 41.4995, "lon": -81.69541}}, {"facility": "Temple University Hospital", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19140", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}, {"facility": "Regeneron Study Site", "city": "Hendersonville", "state": "Tennessee", "zip": "37075", "country": "United States", "geoPoint": {"lat": 36.30477, "lon": -86.62}}, {"facility": "The University of Texas Medical School at Houston", "city": "Houston", "state": "Texas", "zip": "77030", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Intermountain Medical Center", "city": "Murray", "state": "Utah", "zip": "84107", "country": "United States", "geoPoint": {"lat": 40.66689, "lon": -111.88799}}, {"facility": "CHU Dijon", "city": "Dijon", "state": "Bourgogne", "zip": "21000", "country": "France", "geoPoint": {"lat": 47.31667, "lon": 5.01667}}, {"facility": "CHU Reims", "city": "Reims", "state": "Marne", "zip": "51092", "country": "France", "geoPoint": {"lat": 49.25, "lon": 4.03333}}, {"facility": "CHU de Strasbourg - Nouvel Hopital Civil", "city": "Strasbourg", "zip": "67091", "country": "France", "geoPoint": {"lat": 48.58392, "lon": 7.74553}}, {"facility": "Praxis Dr. M. Rolke u. Dr. P. Rueckert", "city": "Aschaffenburg", "state": "Bavaria", "zip": "63739", "country": "Germany", "geoPoint": {"lat": 49.97704, "lon": 9.15214}}, {"facility": "Regeneron Study Site", "city": "Frankfurt am Main", "state": "Hessen", "zip": "60389", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "IKF Pneumologie GmbH & Co. KG - Institut fuer klinische Forschung Pneumologie Frankfurt (Clinical Research Centre Respiratory Medicine) to IKF Pneumologie Frankfurt GmbH & Co KG.", "city": "Frankfurt am Main", "state": "Hessen", "zip": "60596", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "Regeneron Study Site", "city": "Hannover", "state": "Lower Saxony", "zip": "30625", "country": "Germany", "geoPoint": {"lat": 52.37052, "lon": 9.73322}}, {"facility": "Regeneron Study Site", "city": "Koblenz", "state": "Rheinland-Pfalz", "zip": "56068", "country": "Germany", "geoPoint": {"lat": 50.35357, "lon": 7.57883}}, {"facility": "IKF Pneumologie Mainz, Helix Medical Excellence Center Mainz", "city": "Mainz", "state": "Rheinland-Pfalz", "zip": "55128", "country": "Germany", "geoPoint": {"lat": 49.98419, "lon": 8.2791}}, {"facility": "Regeneron Study Site", "city": "Grosshansdorf", "state": "Schleswig-Holstein", "zip": "22977", "country": "Germany", "geoPoint": {"lat": 53.66667, "lon": 10.28333}}, {"facility": "KLB - Gesundheitsforschung Luebeck GmbH", "city": "Luebeck", "state": "Schleswig-Holstein", "zip": "486344", "country": "Germany", "geoPoint": {"lat": 53.86893, "lon": 10.68729}}, {"facility": "Regeneron Study Site", "city": "Berlin", "zip": "12159", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Regeneron Study Site", "city": "Lubin", "state": "Dolnoslaskie", "zip": "59-300", "country": "Poland", "geoPoint": {"lat": 51.40089, "lon": 16.20149}}, {"facility": "Centrum Medycyny Oddechowej, Mroz Spolka Jawna", "city": "Bialystok", "zip": "15-044", "country": "Poland", "geoPoint": {"lat": 53.13333, "lon": 23.16433}}, {"facility": "Lekarze Specjalisci - J. Malolepszy i Partnerzy", "city": "Wroclaw", "zip": "54-239", "country": "Poland", "geoPoint": {"lat": 51.1, "lon": 17.03333}}, {"facility": "Hospital Universitario de Bellvitge", "city": "Barcelona", "zip": "08907", "country": "Spain", "geoPoint": {"lat": 41.38879, "lon": 2.15899}}, {"facility": "Hospital General Universitario Gregorio Maranon (HGUGM) - Instituto de Investigacion Sanitaria Gregorio Maranon (IiSGM)", "city": "Madrid", "zip": "28007", "country": "Spain", "geoPoint": {"lat": 40.4165, "lon": -3.70256}}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.", "infoTypes": ["STUDY_PROTOCOL", "SAP", "ICF", "CSR", "ANALYTIC_CODE"], "timeFrame": "Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.", "accessCriteria": "Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (eg, FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).", "url": "https://vivli.org/"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "127 participants screened, 87 screen-fail, 40 participants randomized", "groups": [{"id": "FG000", "title": "Placebo", "description": "Matching dupilumab placebo"}, {"id": "FG001", "title": "Dupilumab", "description": "A loading dose at the start of the treatment followed by once every two weeks (Q2W)."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "20"}, {"groupId": "FG001", "numSubjects": "20"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "18"}, {"groupId": "FG001", "numSubjects": "20"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Did not complete End of Study follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Placebo", "description": "Matching dupilumab placebo"}, {"id": "BG001", "title": "Dupilumab", "description": "A loading dose at the start of the treatment followed by once every two weeks (Q2W)."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "20"}, {"groupId": "BG001", "value": "20"}, {"groupId": "BG002", "value": "40"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "46.5", "spread": "7.7"}, {"groupId": "BG001", "value": "45.3", "spread": "7.8"}, {"groupId": "BG002", "value": "45.9", "spread": "7.7"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "19"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "12"}, {"groupId": "BG002", "value": "21"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "3"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "19"}, {"groupId": "BG001", "value": "18"}, {"groupId": "BG002", "value": "37"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "3"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "18"}, {"groupId": "BG001", "value": "19"}, {"groupId": "BG002", "value": "37"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline to Week 12 in Constant Work Rate Exercise Endurance Time - CWRET (Constant Work Rate Exercise Test)", "description": "CWRET (Constant Work Rate Exercise Test) will be performed on an electromagnetically-braked cycle ergometer in an exercise physiology laboratory overseen by a trained pulmonologist or medical doctor designee.", "populationDescription": "The full analysis set (FAS) includes all randomized participants. The FAS is based on the treatment allocated (as randomized). Here 'n' = number of evaluable participants at a specified point in time.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Minutes", "timeFrame": "Up to week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching dupilumab placebo"}, {"id": "OG001", "title": "Dupilumab", "description": "A loading dose at the start of the treatment followed by once every two weeks (Q2W)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "20"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.923", "lowerLimit": "-0.614", "upperLimit": "2.460"}, {"groupId": "OG001", "value": "1.742", "lowerLimit": "-0.054", "upperLimit": "3.538"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 12 in Average Number of Steps Walked Per Day", "description": "Based on accelerometry data", "populationDescription": "The full analysis set (FAS) includes all randomized participants. The FAS is based on the treatment allocated (as randomized). Here 'n' = number of evaluable participants at a specified point in time.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Steps", "timeFrame": "Up to week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching dupilumab placebo"}, {"id": "OG001", "title": "Dupilumab", "description": "A loading dose at the start of the treatment followed by once every two weeks (Q2W)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "16"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1066.11", "lowerLimit": "-2921.32", "upperLimit": "789.10"}, {"groupId": "OG001", "value": "925.92", "lowerLimit": "-691.46", "upperLimit": "2543.30"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 12 in Total Energy Expenditure", "description": "Metabolic equivalents of tasks \\[METs\\]. Based on accelerometry data", "populationDescription": "The full analysis set (FAS) includes all randomized participants. The FAS is based on the treatment allocated (as randomized). Here 'n' = number of evaluable participants at a specified point in time.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "METs (metabolic equivalent of task)", "timeFrame": "Up to week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching dupilumab placebo"}, {"id": "OG001", "title": "Dupilumab", "description": "A loading dose at the start of the treatment followed by once every two weeks (Q2W)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "16"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "23.40", "lowerLimit": "-87.37", "upperLimit": "134.17"}, {"groupId": "OG001", "value": "59.36", "lowerLimit": "-15.83", "upperLimit": "134.55"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 12 in the Mean Duration of Moderate-to-vigorous Physical Activity", "description": "Defined as \u22653 METs. Based on accelerometry data", "populationDescription": "The full analysis set (FAS) includes all randomized participants. The FAS is based on the treatment allocated (as randomized). Here 'n' = number of evaluable participants at a specified point in time.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Minutes", "timeFrame": "Up to week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching dupilumab placebo"}, {"id": "OG001", "title": "Dupilumab", "description": "A loading dose at the start of the treatment followed by once every two weeks (Q2W)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "16"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-11.01", "lowerLimit": "-30.52", "upperLimit": "8.50"}, {"groupId": "OG001", "value": "9.38", "lowerLimit": "-13.41", "upperLimit": "32.18"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 12 in Pre- and Post-exercise Forced Expiratory Volume in One Second (FEV1)", "description": "Based on spirometry data", "populationDescription": "The full analysis set (FAS) includes all randomized participants. The FAS is based on the treatment allocated (as randomized). Here 'n' = number of evaluable participants at a specified point in time.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Liters", "timeFrame": "Up to week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching dupilumab placebo"}, {"id": "OG001", "title": "Dupilumab", "description": "A loading dose at the start of the treatment followed by once every two weeks (Q2W)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "20"}]}], "classes": [{"title": "Change from Baseline to Week 12 (Pre-exercise)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "20"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.2123", "lowerLimit": "0.0072", "upperLimit": "0.4174"}, {"groupId": "OG001", "value": "0.4205", "lowerLimit": "0.1409", "upperLimit": "0.7000"}]}]}, {"title": "Change from Baseline to Week 12 (2-min Post-Exercise)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "4"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.2550", "lowerLimit": "-0.2390", "upperLimit": "0.7490"}, {"groupId": "OG001", "value": "0.2902", "lowerLimit": "0.0886", "upperLimit": "0.4919"}]}]}, {"title": "Change from Baseline to Week 12 (5-min Post-Exercise)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "17"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.2416", "lowerLimit": "0.0238", "upperLimit": "0.4593"}, {"groupId": "OG001", "value": "0.4156", "lowerLimit": "0.1505", "upperLimit": "0.6808"}]}]}, {"title": "Change from Baseline to Week 12 (10-min Post-Exercise)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "18"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.2211", "lowerLimit": "0.0180", "upperLimit": "0.4243"}, {"groupId": "OG001", "value": "0.4613", "lowerLimit": "0.2167", "upperLimit": "0.7060"}]}]}, {"title": "Change from Baseline to Week 12 (20-min Post-Exercise)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "20"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.2496", "lowerLimit": "0.0608", "upperLimit": "0.4384"}, {"groupId": "OG001", "value": "0.4738", "lowerLimit": "0.2230", "upperLimit": "0.7245"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Up to 22 weeks", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "Matching dupilumab placebo", "deathsNumAffected": 0, "deathsNumAtRisk": 20, "seriousNumAffected": 0, "seriousNumAtRisk": 20, "otherNumAffected": 9, "otherNumAtRisk": 20}, {"id": "EG001", "title": "Dupilumab 300 mg Q2W", "description": "A loading dose at the start of the treatment followed by once every two weeks (Q2W).", "deathsNumAffected": 0, "deathsNumAtRisk": 20, "seriousNumAffected": 0, "seriousNumAtRisk": 20, "otherNumAffected": 3, "otherNumAtRisk": 20}], "otherEvents": [{"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (26.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 20}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 20}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (26.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 20}]}, {"term": "Sinus pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (26.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 20}]}, {"term": "Injection site erythema", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (26.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 20}]}, {"term": "Rhinitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (26.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 20}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (26.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 20}]}, {"term": "COVID-19", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (26.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 20}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 20}]}, {"term": "Respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (26.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 20}]}, {"term": "Immunisation reaction", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (26.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 20}]}, {"term": "Eye discharge", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA (26.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 20}]}, {"term": "Food poisoning", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (26.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 20}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (26.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 20}]}, {"term": "Sacroiliitis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (26.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 20}]}, {"term": "Tendonitis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (26.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 20}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (26.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 2, "numAtRisk": 20}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 20}]}, {"term": "Syncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (26.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 20}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights."}, "pointOfContact": {"title": "Clinical Trials Administrator", "organization": "Regeneron Pharmaceuticals, Inc.", "email": "clinicaltrials@regeneron.com", "phone": "844-734-6643"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2021-06-17", "uploadDate": "2024-03-21T14:22", "filename": "Prot_000.pdf", "size": 775906}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2023-05-15", "uploadDate": "2024-03-21T14:23", "filename": "SAP_001.pdf", "size": 743940}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}}, "hasResults": true}